Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

EMORY UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1836-12-10

Employees: 10K

Market Cap: -

Website: http://www.emory.edu

Clinical Trials

Asthma Navigator Intervention to Improve Health Equity in Children

Not Applicable

Recruiting

Conditions: Asthma in Children

Interventions: Behavioral: The asthma navigator

First Posted Date: 2024-07-22

Last Posted Date: 2025-01-23

Lead Sponsor: Emory University

Target Recruit Count: 75

Registration Number: NCT06513832

Locations: 🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

Revealing Protective Immunity to Influenza Using Systems Immunology

Phase 4

Recruiting

Conditions: Influenza

Interventions: Biological: Live Attenuated Influenza Vaccine

First Posted Date: 2024-07-15

Last Posted Date: 2024-10-16

Lead Sponsor: Emory University

Target Recruit Count: 50

Registration Number: NCT06501963

Locations: 🇺🇸
Hope Clinic of the Emory Vaccine Center, Decatur, Georgia, United States

Inspiring Seniors Towards Exercise Promotion to Protect Cognition

Not Applicable

Recruiting

Conditions: Alzheimer Disease
Physical Activity

Interventions: Behavioral: Music

First Posted Date: 2024-07-11

Last Posted Date: 2025-03-24

Lead Sponsor: Emory University

Target Recruit Count: 80

Registration Number: NCT06496425

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
UNC Greensboro, Greensboro, North Carolina, United States

Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Advanced Lung Adenocarcinoma
Refractory Lung Adenocarcinoma
Stage III Lung Cancer AJCC v8
Stage IV Lung Cancer AJCC v8

Interventions: Drug: Avutometinib
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Defactinib
Biological: Nivolumab
Procedure: Positron Emission Tomography

First Posted Date: 2024-07-10

Last Posted Date: 2025-04-17

Lead Sponsor: Emory University

Target Recruit Count: 50

Registration Number: NCT06495125

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

Incremental Vestibulo-ocular Reflex Adaptation As a Novel Treatment for Dizziness in People with Multiple Sclerosis

Not Applicable

Recruiting

Conditions: Multiple Sclerosis

Interventions: Device: StableEyes

First Posted Date: 2024-07-10

Last Posted Date: 2025-03-30

Lead Sponsor: Emory University

Target Recruit Count: 138

Registration Number: NCT06495138

Locations: 🇺🇸
Emory Univeristy, Atlanta, Georgia, United States

Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers

Phase 2

Recruiting

Conditions: Fallopian Tube Carcinoma
Malignant Solid Neoplasm
Malignant Uterine Neoplasm
Vulvar Carcinoma
Cervical Carcinoma
Ovarian Carcinoma
Primary Peritoneal Carcinoma

Interventions: Device: Cryocompression Therapy
Other: Best Practice
Drug: Cilostazol
Drug: Paclitaxel
Other: Quality-of-Life Assessment

First Posted Date: 2024-07-09

Last Posted Date: 2024-08-15

Lead Sponsor: Emory University

Target Recruit Count: 70

Registration Number: NCT06492070

Locations: 🇺🇸
Emory University Hospital Midtown, Atlanta, Georgia, United States
🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma

Phase 1

Recruiting

Conditions: Osteosarcoma
Pulmonary Recurrence of Osteosarcoma

Interventions: Procedure: Surgical Resection
Radiation: Stereotactic Body Radiation Therapy (SBRT)
Drug: Atezolizumab

First Posted Date: 2024-07-09

Last Posted Date: 2025-04-23

Lead Sponsor: Emory University

Target Recruit Count: 12

Registration Number: NCT06492954

Locations: 🇺🇸
Chilldren's Healthcare of Atlanta, Atlanta, Georgia, United States

High Dose Radiation Therapy with Pembrolizumab and Chemotherapy for the Treatment of Patients with PD-L1 Positive Metastatic Triple Negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Anatomic Stage IV Breast Cancer AJCC V8
Metastatic Triple-Negative Breast Carcinoma

Interventions: Radiation: Radiation Therapy
Biological: Pembrolizumab
Drug: Nab-paclitaxel
Drug: Paclitaxel
Drug: Carboplatin
Drug: Gemcitabine
Procedure: Biopsy
Procedure: Computed Tomography
Procedure: Bone Scan
Procedure: Biospecimen Collection
Other: Medical Chart Review

First Posted Date: 2024-07-09

Last Posted Date: 2025-03-12

Lead Sponsor: Emory University

Target Recruit Count: 29

Registration Number: NCT06492759

Locations: 🇺🇸
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

Locomotion Adaptation Deficits in Older Adults With Mild Cognitive Impairment and Alzheimers Disease

Not Applicable

Not yet recruiting

Conditions: Alzheimers Disease
Mild Cognitive Impairment

Interventions: Other: 5 Sessions of Split-belt treadmill-based locomotor adaptation
Other: Split-belt treadmill-based locomotor adaptation

First Posted Date: 2024-07-03

Last Posted Date: 2025-04-22

Lead Sponsor: Emory University

Target Recruit Count: 10

Registration Number: NCT06484244

Locations: 🇺🇸
Emory Rehabilitation Hospital, Atlanta, Georgia, United States

A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)

Phase 1

Not yet recruiting

Conditions: Dilated Cardiomyopathy

Interventions: Biological: Allogeneic Neonatal mesenchymal stromal cells (nMSCs)

First Posted Date: 2024-06-18

Last Posted Date: 2025-06-05

Lead Sponsor: Emory University

Target Recruit Count: 36

Registration Number: NCT06464588

Locations: 🇺🇸
Hughes Spalding Children's Hospital, Atlanta, Georgia, United States
🇺🇸
Egleston Children's Hospital, Atlanta, Georgia, United States
🇺🇸
Emory Children's Center, Atlanta, Georgia, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy